Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced its participation in the Jones Las Vegas ...

Anixa Biosciences secured a USPTO patent allowance for its ovarian cancer vaccine, strengthening its IP position and ...

Anixa Biosciences (NASDAQ:ANIX – Get Free Report)‘s stock had its “buy” rating reaffirmed by equities researchers at HC ...

Fintel reports that on March 21, 2025, Maxim Group initiated coverage of Anixa Biosciences (NasdaqCM:ANIX) with a Buy ...

Anixa Biosciences signed a letter of intent with VERDI Solutions to develop AI-powered personalized and off-the-shelf cancer ...

Anixa Biosciences has a 1 year low of $2.07 and a 1 year high of $4.20. The firm’s fifty day simple moving average is $2.95 and its 200 day simple moving average is $3.01.

Anixa Biosciences inks LoI with VERDI Solutions to develop artificial intelligence-guided personalized and off-the-shelf peptide vaccines for cancer: San Jose, Calif Friday, March ...

Anixa Biosciences (ANIX) announced that the United States Patent and Trademark Office, USPTO, has issued a Notice of Allowance for a key patent ...

The firms hope to show that Verdi's off-the-shelf peptide cancer vaccine can shrink tumors and improve quality of life in patients with bone metastases.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...